Eli Lilly receives its only sell rating from HSBC, which cites smaller market for weight-loss drugs
Eli Lilly slipped in early trading after analysts at HSBC gave the pharmaceutical darling at the center of the obesity drug boom a rare downgrade.
Analysts at the bank cut their rating to “reduce” from “hold.” They cut their price target to $850 from $1,070. The stock closed at $989 on Monday.
According to Bloomberg, this is the only sell rating on Lilly among the 38 analysts who cover the stock.
The company has rallied more than 20% in the past year as its obesity drug sales continue to rise, far outpacing its top rival, Novo Nordisk. But the space is getting increasingly crowded with new entrants as well as new products from Lilly and Novo, putting downward pricing pressure on their products.
HSBC: ".. We downgrade Lilly to Reduce (from Hold) as we cut our medium-term forecasts for the market .. We think Lilly shares are priced to perfection .. and think medium-term earnings trends are optimistic. .. the total addressablemarket (TAM) for obesity might be USD80-120bn (not >USD150bn)."
— Carl Quintanilla (@carlquintanilla.bsky.social) March 17, 2026 at 12:24 PM